GlaxoSmithKline lung drug Anoro approved in Europe

LONDON Thu May 8, 2014 11:39am EDT

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008.  REUTERS/Toby Melville

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008.

Credit: Reuters/Toby Melville

Related Topics

LONDON (Reuters) - GlaxoSmithKline said on Thursday its new inhaled lung drug, Anoro, had been approved in Europe as a treatment for chronic lung disease, boosting its respiratory franchise.

A final green light had been expected for the product, which was developed with Theravance, following a recommendation from European experts in February.

Respiratory drugs are a major business for GSK. Advair or Seretide, its market-leading lung drug, makes up a fifth of its sales, but it is already facing competition from generic versions in Europe.

Industry analysts expect Anoro to generate worldwide annual sales of about $2.65 billion by 2019, according to Thomson Reuters data.

(Reporting by Ben Hirschler; editing by Jane Baird)

FILED UNDER: